African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians.
about
Novel Alpha Interferon (IFN- ) Variant with Improved Inhibitory Activity against Hepatitis C Virus Genotype 1 Replication Compared to IFN- 2b Therapy in a Subgenomic Replicon SystemRandomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naïve patients with chronic hepatitis CCytopathic and Noncytopathic Interferon Responses in Cells Expressing Hepatitis C Virus Subgenomic RepliconsChronic hepatitis C treatment patterns in African American patients: an update.Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, CaliforniaPathogen-pathogen interaction: a syndemic model of complex biosocial processes in diseaseUltra-rapid virological response, young age, low γ-GT/ALT-ratio, and absence of steatosis identify a subgroup of HCV Genotype 3 patients who achieve SVR with IFN-α(2a) monotherapy.Hepatitis C virus (HCV) genotypes in the Caribbean island of Martinique: evidence for a large radiation of HCV-2 and for a recent introduction from Europe of HCV-4Coinfection with HIV and hepatitis C virus in injection drug users and minority populations.Hepatitis C virus infection in African Americans.Chronic hepatitis C virus management: 2000-2005 update.Treating hepatitis C in African Americans.Racial disparity in liver disease: Biological, cultural, or socioeconomic factors.Demographics of a large cohort of urban chronic hepatitis C patients.Effect of race and HIV co-infection upon treatment prescription for hepatitis C virus.Decreasing racial disparity with the combination of ledipasvir-sofosbuvir for the treatment of chronic hepatitis CSystematic review: epidemiology of hepatitis C genotype 6 and its management.Future therapies for chronic hepatitis C.Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: does ethnicity matter?Racial diversity in mortality and morbidity in urban patients with hepatitis C.Effect of Treatment for CHC on Liver Disease Progression and Hepatocellular Carcinoma Development in African Americans.The Role of FGL2 in the Pathogenesis and Treatment of Hepatitis C Virus Infection.Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin.A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C.Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*.Pretreatment assessment and predictors of hepatitis C virus treatment in US veterans coinfected with HIV and hepatitis C virus.Correlation between insulin resistance and outcome of pegylated interferon and ribavirin therapy, hepatic steatosis, hepatic fibrosis in chronic hepatitis C-1b and high viral load.Comparison of 125I-interferon-alpha binding to peripheral blood cells from African-Americans and Caucasians with hepatitis C.Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C.A comparison of the natural history and outcome of treatment for Asian and non-Asian hepatitis C-infected patients.
P2860
Q27477758-B43BC5B6-2497-4332-81ED-33B1720DC5E1Q27477967-86B0BB8C-F5C3-4E8F-9744-46911431D65CQ27485424-F31653C0-3E0F-4230-AF37-05C9DC2C4575Q33212476-E4CE385C-63D4-4209-9AD7-9E619FFEE995Q33978978-579961AD-B267-48DA-A24D-115292CFCB0CQ34824481-D3A5D0BC-8D56-4B8C-8519-9AAE8A4BE707Q35529369-BB6A1125-61D5-47C9-854D-7FC2DB020C58Q36240052-6708AF94-FC10-4908-8C8D-12E1400C9662Q36304424-69FDD844-E731-49AB-AD66-2EDF57565470Q36328945-BD0FCBAF-8063-490A-A5A7-3F2646D7AA13Q36348376-A94D4489-8884-4ECF-ADE5-4D8FB6C25394Q36758665-9544DA28-C0F3-4746-B733-CBC3DBCAB455Q37095472-F688D638-AFD1-4CF6-B543-4EB41FF48F82Q37278212-8BC2A467-7AC5-47DF-87AC-1CCD5571B888Q37317173-74DC800D-6081-439E-AE32-BE19723F80DEQ37714088-14B3B4B5-0927-461C-97ED-593DAF54D63EQ37882006-701E18AC-0BBE-4A92-B501-A9452CFD6725Q38082566-7ED79C7E-EAB5-404C-9226-1E946388557EQ39337505-A5A09850-E290-4DDA-AD51-91B708EAF3DAQ40348098-D046E8A8-79F8-40E2-B350-D65E5509B949Q41084425-D243EF2F-A0A5-47BC-B1F6-C6F4856A82CDQ41992660-DC0FC61F-4250-46F6-B31A-8589097242F4Q42978398-4F96827D-C7F0-4F44-849E-4AAA502834B7Q42996520-70E8AD94-2A06-4CFA-A708-25EE7E918747Q42999426-048C5DE8-AA87-4B71-8211-4FB2ECD44733Q43033701-BD5366CA-4D6D-4119-A8F4-181A5F5EBC2EQ43047753-D3CD6366-76A5-4FFC-B3DD-F3BBB327C24AQ44895754-FCFAAE53-B95F-4B30-B9C1-A51CD5755763Q46866205-192A40A3-C938-4CF1-80F0-2DCCF2FDB246Q50532082-FA970FED-0436-46FD-8140-B3E8365912FB
P2860
African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
African Americans with genotyp ...... ment response than Caucasians.
@en
African Americans with genotyp ...... ment response than Caucasians.
@nl
type
label
African Americans with genotyp ...... ment response than Caucasians.
@en
African Americans with genotyp ...... ment response than Caucasians.
@nl
prefLabel
African Americans with genotyp ...... ment response than Caucasians.
@en
African Americans with genotyp ...... ment response than Caucasians.
@nl
P2093
P2860
P1476
African Americans with genotyp ...... ment response than Caucasians.
@en
P2093
Ehrinpreis MN
Janisse JJ
Massanari M
Mutchnick MG
Nathani MG
Peleman RR
P2860
P304
P356
10.1046/J.1365-2893.2001.00292.X
P577
2001-07-01T00:00:00Z